Novocure Ltd reports results for the quarter ended March 31 - Earnings Summary

NovoCure

24/04/2025 14:33

Novocure Ltd NVCR.OQ reported a quarterly adjusted loss of 31 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -36 cents.  The mean expectation of seven analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -74 cents to -26 cents per share.

Revenue rose 11.9% to $154.99 million from a year ago; analysts expected $146.60 million.

Novocure Ltd's reported EPS for the quarter was a loss of 31 cents​.

The company reported a quarterly loss of $34.32 million.

Novocure Ltd shares had fallen by 0.3% this quarter and lost 40.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 19.5% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Novocure Ltd is $33.50

This summary was machine generated from LSEG data April 24 at 01:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.46
-0.31
Beat
Dec. 31 2024
-0.34
-0.61
Missed
Sep. 30 2024
-0.33
-0.28
Beat
Jun. 30 2024
-0.41
-0.31
Beat